Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681119 | 0.84 | MAPT (0.56) | PARP15PARP10PARP2ACHECDK1 | |
| SCHEMBL20830742 | 0.80 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4ACHE | |
| SCHEMBL3468807 | 0.80 | PARP15 (0.54) | CHRNB2CHRNA7CHRNA4PARP15PARP10 | |
| SCHEMBL795937 | 0.79 | MAPT (0.61) | PARP15PARP10PARP2ACHE | |
| SCHEMBL6928149 | 0.79 | GABRA5 (0.57) | — | |
| SCHEMBL10932224 | 0.78 | PARP10 (0.70) | CHRNB2CHRNA7CHRNA4PARP15PARP10 | |
| SCHEMBL11661187 | 0.78 | MAPK1 (0.50) | CHRNB2CHRNA7CHRNA4PARP15PARP10 | |
| SCHEMBL17220078 | 0.78 | ACHE (0.49) | PARP15PARP10PARP2ACHE | |
| SCHEMBL20023724 | 0.77 | ACHE (0.46) | PARP15PARP10PARP2ACHE | |
| SCHEMBL30447289 | 0.77 | ACHE (0.46) | PARP15PARP10PARP2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | CHRNB2 101/4885CHRNA7 58/4885CHRNA4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.